PROPHYLAXIS with ofloxacin decreases the incidence of moderate-to-severe adverse effects from bacillus Calmette-Guérin (BCG) intravesical therapy in patients with superficial bladder cancer, French researchers reported. Ofloxacin is a fluoroquinolone with tuberculostatic properties.